Abstract: A B7-H3 targeting antibody-drug conjugate, and a preparation method therefor and use thereof. Provided is the antibody-drug conjugate as shown in formula I. The compound has a good targeting property, good inhibitory effect on tumor cells positively expressing B7-H3, and good druggability and safety. The present antibody-drug conjugate has an inhibitory effect against B7-H3, and also a good inhibitory effect against at least one of NCI-N87, A375, LN-229, PA-1, MDA-MB-468, Calu-6 and HS-700T cells.

Abstract: A TROP2 targeting antibody-drug conjugate, and a preparation method and use therefor. The antibody-drug conjugate is shown in formula I. Said type of compound has a good targeting property, a good inhibitory effect on tumor cells positively expressing TROP2, and good druggability and high safety. The present antibody drug conjugate has an inhibitory effect on TROP2, and also a good inhibitory effect on at least one of NCI-N87, MDA-MB-468 and BXPC3 cells.

Abstract: An antibody-drug conjugate, and an intermediate thereof, a preparation method therefor, and an application thereof. Provided is an antibody-drug conjugate as represented by formula I. The compound has good targetability, has a good inhibitory effect on HER3-positive tumor cells, and has good druggability and high safety. The antibody-drug conjugate has an inhibitory effect on HER3, has an inhibitory effect on SK-BR-3 and SW620 cells, and also has a good inhibitory effect on at least one of 22Rv1, LNCaP, NCI-H820, OVCAR-8, and HCC827 cells.

Abstract: Disclosed are an antibody-drug conjugate (ADC), an intermediate thereof, a preparation method therefor and an application thereof. The present invention provides an ADC. A structural general formula thereof is Ab-(L3-L2-L1-D)m. The ADC has better biological activity, stability, and uniformity, has reduced toxic and side effects, and has a faster release rate of enzyme cutting in tumor cells. The use of the novel ADC can achieve a wide application of a cytotoxic drug particularly camptothecin in the field of ADCs in treating tumor patients resistant to microtubule ADC.

Abstract: An application of an antibody conjugate in the preparation of a drug for treating CD30 positive tumors, which is characterized in that: the antibody conjugate is F0002-ADC; the general formula of the structural thereof is Ab-Lm-Yn; and the CD30-positive tumors are CD30-positive tumors that express a multidrug resistance gene 1. In addition, a pharmaceutical combination and a pharmaceutical composition containing the antibody conjugate, which may be applied to the preparation of a drug used for treating CD30-positive tumors.

Abstract: An anti-B7-H3 antibody, a preparation method therefor, a conjugate and an application thereof. The anti-B7-H3 antibody comprises a complementarity determining region: one or more of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3. A sequence of the complementarity determining region is as described in the specification. The anti-B7-H3 antibody is a fully human antibody, has a unique antigen binding epitope, and can specifically bind B7-H3 antigen on tumor cells. Moreover, the antibody can rapidly internalize into cells after binding to tumor cells, and can be used for ADC drug development to obtain better anti-tumor activity and efficacy to achieve the purpose of treating cancers.

Abstract: A low-frequency band suppression enhanced anti-reversal power system stabilizer is presented by the invention. Currently the widely used PSS2B power system stabilizer needs lead elements above Order 2 to meet the phase compensation requirement of DC blocking signal of active power, thus quickly increasing high-frequency band gain, restricting allowable total setting gain of PSS, limiting low-band gain and reducing low-frequency band suppression ability of power system stabilizer. The invention will add generator speed signal ? (which is treated by DC blocking element and corrected by parallel proportional differential PD) and active power signal Pe (which is treated by DC blocking element and gained by gain factor Ks3) to get equivalent synthetic mechanical power of power system stabilizer.

Abstract: A low-frequency band suppression enhanced anti-reversal power system stabilizer is presented by the invention. Currently the widely used PSS2B power system stabilizer needs lead elements above Order 2 to meet the phase compensation requirement of DC blocking signal of active power, thus quickly increasing high-frequency band gain, restricting allowable total setting gain of PSS, limiting low-band gain and reducing low-frequency band suppression ability of power system stabilizer. The invention will add generator speed signal ? (which is treated by DC blocking element and corrected by parallel proportional differential PD) and active power signal Pe (which is treated by DC blocking element and gained by gain factor Ks3) to get equivalent synthetic mechanical power of power system stabilizer.

Abstract: A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.

Abstract: A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.